| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1175 | Bw284c51 | Highly selective inhibitor of AChE |
|
| DCC1176 | Bxl0124 | Novel Gemini vitamin D analog, targeting CD44-STAT3 signaling and inhibiting breast cancer invasion |
|
| DCC1177 | Bz(1,2,4,5)p4 | Novel promising spectroscopic probe for inositol 5-phosphatase(s) |
|
| DCC1178 | Bzn-ejj-amide | Novel potent and selective PTP-1B inhibitor |
|
| DCC1179 | C[pro-arg-phe-phe-asn-ala-phe-dpro] | β-Hairpin Octapeptide, acting as a potent mouse melanocortin-4 receptor (mMC4R) antagonist |
|
| DCC1180 | C000000956 | Natural inhibitor of BACE1 |
|
| DCC1181 | C012 Dihydrochloride | Novel sensitizer of BRAF wild-type melanoma cells to vemurafenib, significantly reducing melanoma cell viability, with limited toxicity for normal human fibroblasts |
|
| DCC1182 | C10-pr-spn | Novel broad-spectrum intracellular targeting antibacterial agent, interacting with the 70S ribosome of E. coli and inhibiting its protein synthesis, demonstrating superior clearance of bacteria from the spleen, liver, and kidneys of mice, infected with S. |
|
| DCC1183 | C12-pr-spn | Novel broad-spectrum intracellular targeting antibacterial agent, interacting with the 70S ribosome of E. coli and inhibiting its protein synthesis, demonstrating superior clearance of bacteria from the spleen, liver, and kidneys of mice, infected with S. |
|
| DCC1184 | C15alkopp | FPP analogue, bearing an alkyne group to allow for post-prenylation protein labeling |
|
| DCC1185 | c1-resveratrol | Novel multi-functional resveratrol derivative for the treatment of atrial fibrillation |
|
| DCC1186 | C3001a | Novel selective activator for TREK, against other two-pore domain K (K2P) channels |
|
| DCC1187 | C3-005 | First-In-Class Inhibitor of the Interaction between Bacterial RNA Polymerase and Sigma Initiation Factor, Affecting the Viability and Toxin Release of Streptococcus pneumoniae |
|
| DCC1188 | C3b Inhibitor Cmp-5 | The first C3b-binding complement inhibitor, inhibiting the formation of the membrane attack complex (MAC) by preventing cleavage of C5 |
|
| DCC1189 | C48/80 | Inducer of mast cell degranulation |
|
| DCC1190 | C562-1101 | Novel potent inhibitor of botulinum neurotoxin serotype E (BoNT/E) |
|
| DCC1191 | C5-chem-clip | Novel covalent cross-linker to the SARS-CoV-2 frameshifting element (FSE), directly targeting engagement of the SARS-CoV-2 FSE in cells, dose dependently reducing frameshifting in cells expressing the SARS-CoV-2 FSE, with no significant effect on frameshi |
|
| DCC1192 | Ca Ix/xii Inhibitor | Selective inhibitor of hCA IX and hCA XII |
|
| DCC1193 | Ca-074 | Potent and selective inhibitor of cathepsin B |
|
| DCC1194 | Caa0225 | Novel specific inhibitor of cathepsin L, effectively inhibiting degradation of LC3-II and GABARAP |
|
| DCC1195 | Cabdf1 Bd1 Inhibitor 1 | Novel selective CaBdf1 BD1 inhibitor |
|
| DCC1196 | Cabdf1 Bd1 Inhibitor 3 | Novel inhibitor of CaBdf1 BD1 with low-micromolar affinity and three- to fivefold selectivity relative to human Brd4 BD1 |
|
| DCC1197 | Cabdf1 Bd2 Inhibitor-2 | Novel selective CaBdf1 BD2 inhibitor |
|
| DCC1198 | Cacc(inh)-b01 | Potent, selective class B inhibitor of calcium-activated chloride channels (CaCCs) |
|
| DCC1199 | Caged Az-13767370 | Novel photocaged ERK1/2 inhibitor as a light-controlled anticancer agent |
|
| DCC1200 | caged Gc-1 | Potent agonist at thyroid hormone receptor (TR) |
|
| DCC1201 | Ca-in-5g | Effective inhibitor of the carbonic anhydrase (CA) from Trypanosoma cruzi (TcCA) |
|
| DCC1202 | cal-130 | Novel inhibitor of p110 |
|
| DCC1203 | Calcein-am Featured | Cell permeable derivative of calcein, becoming fluorescent on hydrolysis |
|
| DCC1204 | Calcium Dibesilate | Dual inhibitor of fibroblast growth factors (FGF) and vascular endothelial growth factor (VEGF) ; Anti-angiogenic |
|
